Key statistics
On Monday, Alpha Tau Medical Ltd (DRTS:NAQ) closed at 2.27, 29.71% above the 52 week low of 1.75 set on Jun 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.35 |
---|---|
High | 2.36 |
Low | 2.26 |
Bid | 2.15 |
Offer | 2.47 |
Previous close | 2.28 |
Average volume | 15.22k |
---|---|
Shares outstanding | 69.92m |
Free float | 52.00m |
P/E (TTM) | -- |
Market cap | 159.43m USD |
EPS (TTM) | -0.3966 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 20:59 BST.
More ▼
Announcements
- Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
- Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
- Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
- Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
- Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
- Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
- Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
More ▼